Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
用户lD2HN5W0jm0A
22小时前
22
10
待确认
帖子自动结束时间: 2025-06-18 13:31:19
1. 请及时下载文件确认是否正确, 系统将在 2025-06-20 14:21:01 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
X Zhu, M Zheng, M Song, YK Shen, D Chan…
Journal of drugs in …, 2013
europepmc.org
… The LOTUS study is a phase 3, double-blind, placebo-controlled study that evaluated the efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis. Patients and methods … Consistent with results previously reported in global phase 3 studies, ustekinumab was highly effective and generally well tolerated in Chinese patients with moderate to severe psoriasis through 36 weeks. …
